Australia’s Vaccine Value Chain Conference
21st – 22nd May 2024 •
Sydney, NSW
An exclusive thought leadership event, bridging the gaps in Australia’s vaccine ecosystem to maximise health impact and unlock the nation’s economic potential in global disease prevention.
Overview
Biointelect recently convened the inaugural Vaccine Value Chain Conference which was attended by 230 experts from across the vaccine community. This exclusive thought leadership event explored how we can bridge the gaps in Australia’s vaccine ecosystem to maximise health impact and unlock the nation’s economic potential in global disease prevention.
Location
Doltone House Hyde Park, Sydney, New South Wales, Australia
Time Start/End
8:00 am, 21st May – 5:30pm 22nd May
Gallery
Day 1
8:00am – 8:30am
Registration
Coffee, Tea and Refreshments
8:30am – 8:50am
Opening of the Conference
Welcome to Country and Opening Remarks
8:50am – 10:15am
Plenary 1:
The Vaccine Value Chain – What Do We Want for Australia?
10:15am – 10:45am
Morning Tea and Networking
10:45am – 12:00pm
Plenary 2:
Preclinical Vaccine Development Capabilities in Australia: Governance, Skills and Talent
12:00pm – 1:00pm
Lunch and Networking Event
1:00pm – 2:15pm
Plenary 3:
Clinical Trials and Infrastructure
2:15pm – 3:30pm
Plenary 4:
Manufacturing: Supply, Demand and Sustainability
3:30pm – 4:30pm
Afternoon Tea and Networking
4:00pm – 5:30pm
Plenary 5:
Enabling Policy and Regulation for Vaccines
6:00pm – 7:00pm
Pre-dinner Drinks
Venue: Strangers Foundation Room, NSW Parliament
Pre-dinner remarks:
Leah Goodman, CEO Biointelect & The Hon Anoulack Chantivong MP Minister for Innovation, Science and Technology
7:00pm – 10:00pm
Dinner and Evening Networking
Day 2
8:00am – 8:30am
Coffee, Tea and Refreshments
8:30am – 8:50am
Special Session:
How Can Australia Contribute to Advance CEPI’s 100 Day Mission and the Regional Vaccine Manufacturing Collaborative?
9:45am – 11:00am
Plenary 6:
Equity of Access and Uptake
11:00am – 11:30am
Morning Tea and Networking
11:30am – 12:45pm
Plenary 7:
Market Access and Health Technology Assessment
12:45pm – 1:45pm
Lunch and Networking Event
1:45pm – 3:00pm
Plenary 8:
Funding and Investment
3:00pm – 3:40pm
Plenary 9:
Bringing it All Together/The Vaccine Value Chain
3:40pm – 3:50pm
Closing Remarks
4:15pm – 5:30pm
CSIRO Satellite Session:
Advancing Innovation in Australian Veterinary Vaccines
Sessions
Day 1
Opening Remarks
Jennifer Herz
Co-founder and Director, Biointelect
Brett Sutton
Director of Health & Biosecurity at CSIRO, Australia’s national science agency.
Recorded Presentation
The Hon Ged Kearney MP
Assistant Minister for Health and Aged care
Vaccine Value Chain and Global Ecosystem
Speakers
Eric Claaasen
Chief Executive Officer, Vironovative BV
Linda van de Burgwal
Associate Professor Societal Entrepreneurship and Innovation in Health and Life Sciences, Athena – Research and Education Institute
BactiVac – The UK-based global Network accelerating the development of vaccines against AMR-relevant bacterial pathogens
BactiVac – The UK-based global Network accelerating the development of vaccines against AMR-relevant bacterial pathogens.pdf
Adam Cunningham
Co-Director, Bacterial Vaccine Network (BactiVac)
Australian Value Vaccine Chain
Speakers
Jennifer Herz
Co-founder and Director, Biointelect
Esther Pronker
Consultant, Biointelect
The UK Vaccine Network and Comparison with Australia
Alex Spencer
Immunology Lecturer, University of Newcastle
Overseas Example CARB-X Accelerator and Learnings
Speakers
Richard Alm
Chief Scientist Officer, Carb-X
What’s New in Optimising Preclinical Vaccine Research
Speakers
Deborah Burnett
Group Leader, Garvan Institute of Medical Research
Collaborative Research Between Academic and Industry Scientists Drives Vaccine Development
Collaborative Research Between Academic and Industry Scientists Drives Vaccine Development.pdf
Speakers
Tony Cunningham
Director, Centre for Virus Research, The Westmead Instiute for Medical Research
Health Security Systems Australia: Reflections from Medical Countermeasures Program and Australian Capability Audit
Speakers
Felicia Pradera
Head, Health Security Systems Australia
Attracting Industry Investment in R&D, the Translational Science Hub as an Example
Speakers
Iris Depaz
Managing Director Translational Science Hub, Sanofi
Clinical Development Challenges in Global Clinical Trials, What Do Sponsors Look For?
Speakers
Cheryl Keech
Consultant in Strategic Clinical Development
Australia’s Strengths in Early Phase Trials and Capability Gaps
Speakers
Paul Griffin
Director of Infectious Disease, Mater Hospital
Australian Capability and Contribution to Clinical Trials
Speakers
Peter Richmond
Head, Vaccine Trials Group, Telethon Kids Institute
Regional Clinical Trial Capability and Impact on Policy in Asia-Pacific
Speakers
Fiona Russell
Group Leader Asia-Pacific Health Research, Murdoch Children’s Research Institute
Perspective on the Government Investment and Current/Planned Australian Manufacturing Capability
Perspective on the Government Investment and Current/Planned Australian Manufacturing Capability.pdf
Speakers
Louise Talbot
General Manager, Industry and Manufacturing Division, Department of Industry, Science and Resources
Local Manufacturer’s Perspective on Supply, Demand, and Sustainability
Speakers
Chris Larkins
Vice President – Operation, CSL Seqirus
Global Supply Chain Perspective on Supply, Demand, and Sustainability
Speakers
Andrew Watson
Director, CBE Pty Ltd
Biotech Perspective on Supply, Demand, Sustainability and Logistics of Delivery
Speakers
Angus Forster
Chief Technology Officer, Vaxxas
Australia’s Vaccination Space: Exciting Developments and What We Have Learned from the Pandemic
Speakers
Paul Kelly
Chief Medical Officer, Australian Government Department of Health and Aged Care
The Platform Approach for Facilitating Vaccine Development and Regulation: MRNA as an Example
Speakers
John Skerritt
Enterprise Professor for Health Research Impact, University of Melbourne
Vaccine Surveillance and Vaccine Safety
Speakers
Kristine Macartney
Director, National Centre for Immunisation Research & Surveillance
Industry Perspectives on Pandemic Learnings and Enabling Regulatory Pathways
Speakers
Carolyn Tucek-Szabo
Senior Director Global Regulatory Sciences Lead Australia/New-Zealand, Moderna
Animal Health Vaccines: Regulatory Barriers and Opportunities for Alignment
Speakers
Ben Stapley
Chief Executive Officer, Animal Medicines Australia
Day 2
Australia Case Study Series
Update from CEPI (Recorded presentation)
Speakers
Frederik Kristensen
Managing Director Regionalized Vaccine Manufacturing Collaborative (RMVC)
Case Study One
Speakers
Keith Chappell
Professor, Australian Insitute for Bioengineering and Nanotechnology, The University of Queensland
Case Study Two
Speakers
Jamie Triccas
Deputy Director, Sydney Infectious Diseases Institute, The University of Sydney
Case Study Three
Speakers
Anne Collins
Chief Executive Officer, Sementis
Improving Vaccine Confidence, Equity and Uptake (in Australia and the Asia Pacific region)
Speakers
Margie Danchin
Group Leader, Vaccine Uptake, MCRI in addition to Deputy Chair, ARIA
Strategies to Increase Vaccine Uptake in Primary Care
Speakers
Nigel Stocks
Director, Australian Sentinel Practices Research Network
Pharmacy Role in Increasing Adult Vaccine Uptake
Speakers
Chris Campbell
General Manager, Policy and Program Delivery, Pharmaceutical Society of Australia
Achieving Equity in Underserved Populations
Speakers
Kristy Crooks
Aboriginal Program Manager and leads Public Health Aboriginal Team, Health Protection – Hunter New England
Perspectives on How Vaccines are Valued
Speakers
Natalie Carvalho
Associate Professor of Health Economomics, Melbourne School of Population and Global Health, University of Melbourne
Clinical Research Perspectives on HTA, Value of Vaccines and Evidence Generation
Speakers
Michelle Giles
Professor, Department of Infectious Disease, University of Melbourne
Industry Perspectives On HTA Review Priorities for Vaccines
Speakers
Andrew Thirlwell
Global Policy and Public Affairs, Australia, New-Zealand and Korea Lead, Pfizer
Reflections: PBAC, HTA and Vaccines
Speakers
Michelle Burke
PBAC Member
Medical Research Future Fund Update
Speakers
Pru Glasson
Director Translation and Commercialisation Section, Australian Government Department of Health and Aged Care
How Industry Makes Investment Decisions
Speakers
Patrick Desbiens
Senior Vice President & General Manager Australia, GSK
Accelerating Vaccines with Limited Commercial Potential, the Strep A Example
Speakers
Jonathan Carapetis
Executive Director, Telethon Kids Institute
Global Venture Capital and Private Equity Investment
Speakers
Eric Claassen
Chief Executive Officer, Vironovative BV
Panel Discussion
Panelists
Jodie McVernon
Professor and Director of Doherty Epidemiology
Kylie Sproston
Chief Executive Officer, Bellberry Limited
Sue MacLeman
Advisor and Non Executive Director, Medical Technology and Pharmaceutical (MTP)
Ian Henderson
Executive Director, Institute for Molecular Bioscience, University of Queensland
Chris Smith
Partner, Brandon Capital
Experience of SMEs in Australia’s Veterinary Vaccine Space
Speakers
Robin Achari
Senior Technical Veterinarian, Bioproperties
Experience of Multinational Companies in Australia’s Veterinary Vaccine Space
Speakers
Kishore Prayaga
Director, Veterinary Medicine R&D, Zoetis
Development and Negotiations for New Veterinary Vaccine Technologies – EMAI/NSW DPI mRNA Vaccine Project
Speakers
Paul Hick
Research Coordinator, Veterinary Virology, Elizabeth Macarthur Agricultural Institute (EMAI), NSW Department of Primary Industries (NSW DPI)
Biosecurity Policy Review: A Secure Future for Imports of Veterinary Vaccines
Speakers
Nathan Jamieson
Director, Department of Agriculture, Fisheries and Forestry (DAFF) Animal and Biological Import Branch
Regulatory Approaches for Veterinary Vaccine Platform Technologies – Challenges and Opportunities
Speakers
Mariette van Den Berg
Assistant Director Veterinary Medicines, Australian Pesticides and Veterinary Medicines Authority
Sponsors
